V710 + Placebo

Phase 2/3Terminated

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Staphylococcus Aureus

Conditions

Staphylococcus Aureus, Bacteremia, Mediastinitis

Trial Timeline

Dec 1, 2007 → Aug 1, 2011

NCT ID

NCT00518687

About V710 + Placebo

V710 + Placebo is a phase 2/3 stage product being developed by Merck for Staphylococcus Aureus. The current trial status is terminated. This product is registered under clinical trial identifier NCT00518687. Target conditions include Staphylococcus Aureus, Bacteremia, Mediastinitis.

What happened to similar drugs?

2 of 4 similar drugs in Staphylococcus Aureus were approved

Approved (2) Terminated (0) Active (2)

✅Imipenem/cilastatinPfizerApproved

✅linezolid (Zyvox) + vancomycinPfizerApproved

🔄Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + ClindamycinAbbViePhase 3

🔄Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00735839	Phase 1	Completed	Mar 1, 2008	Jun 1, 2008	Staphylococcal Infection
NCT00518687	Phase 2/3	Terminated	Dec 1, 2007	Aug 1, 2011	Staphylococcus Aureus

Competing Products

12 competing products in Staphylococcus Aureus

See all competitors

Product	Company	Stage	Hype Score
Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin	AbbVie	Phase 3	40
AZD7760	AstraZeneca	Phase 1/2	39
Daptomycin	Merck	Phase 2	35
Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO)	Merck	Phase 2	35
Imipenem/cilastatin	Pfizer	Approved	39
linezolid (Zyvox) + vancomycin	Pfizer	Approved	43
Linezolid + Vancomycin	Pfizer	Pre-clinical	26
Aurexis®	Bristol Myers Squibb	Phase 2	35
Aurexis® (tefibazumab)	Bristol Myers Squibb	Phase 2	35
blood samples + nasal swabs	Sanofi	Pre-clinical	26
Ceftobiprole medocaril + Daptomycin	Basilea Pharmaceutica	Phase 3	34
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II	XBiotech	Phase 1/2	22